Mr Kevin Bitterman

KANDO id: 77210

Bio

Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases. Kevin has authored papers in several top tier journals, is an inventor on multiple patents and is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK). Kevin currently represents Polaris as a Director of Biolex Therapeutics, EPacing Inc., Follica Inc., Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Taris Biomedical, and Visterra. Additionally, Kevin is a Board Observer to Pulmatrix Inc. Prior to obtaining his Ph.D. at Harvard Medical School, Kevin earned a B.A. with Highest Honors from Rutgers College with a major in Biological Sciences and a minor in Philosophy.

Career


Polaris Venture Partners Inc

Multistage venture capital investors with focus Technology, Healthcare and Consumer

Education